In the setting of HSP-targeted therapies, the hypothesis that the induction of HSP27, in reason of HSP90 inhibition, is a mechanism to bypass treatment-induced apoptosis has already been tested in prostate cancer [48]. This evidence concerns the gene HSP90B2P and prostate carcinoma.